Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Russell Goode

Orthopaedic Surgery Mobile, AL Medical Doctor

NPI 1518278126 CMS profile 1283539

1720 Spring Hill Ave Ste 3, Mobile, AL 36604

Open in the dashboard

General payments

$43,403

168 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,500 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Russell Goode of Mobile, AL is reported in the CMS Open Payments database as having received $43,403 across 168 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,500 28
2024 General $7,199 18
2023 General $8,851 27
2022 General $8,665 25
2021 General $1,962 30
2020 General $6,249 21
2019 General $3,978 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Russell Goode
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Russell Goode were reported at $6,500. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Russell Goode Orthopaedic Surgery median Middle half National median
2019 $3,978 $644 $140–$2,844 $163
2020 $6,249 $312 $75–$1,860 $114
2021 $1,962 $520 $117–$2,495 $132
2022 $8,665 $598 $128–$2,731 $149
2023 $8,851 $461 $128–$2,264 $160
2024 $7,199 $497 $134–$2,475 $164
2025 $6,500 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $20,305 33 payments
  2. Synthes GmbH $7,129 6 payments
  3. Synthes USA Products LLC $6,538 7 payments
  4. Arthrex, Inc. $3,825 6 payments
  5. IlluminOss Medical, Inc. $1,022 2 payments
  6. DePuy Synthes Sales Inc. $974 12 payments
  7. Prime Surgical, LLC $936 4 payments
  8. Amgen Inc. $694 25 payments
  9. Radius Health, Inc. $393 15 payments
  10. Djo, LLC $350 11 payments
  11. Other $1,237 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $23,209 7 payments
  2. Travel and Lodging $7,065 17 payments
  3. Food and Beverage $5,123 139 payments
  4. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $5,000 2 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,000 2 payments
  6. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. TFN-Advance $1,072 7 payments
  2. Photodynamic Bone Stabilization Procedure Pack $1,000 1 payment
  3. Velys $572 8 payments
  4. EVENITY $522 20 payments
  5. Prolia $418 21 payments
  6. CMF $296 9 payments
  7. NA $219 5 payments
  8. Tymlos $159 11 payments
  9. PALACOS $129 7 payments
  10. Exogen Ultrasound Bone Healing System $122 3 payments
  11. Other $1,589 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

850

Median for Orthopedic Surgery: 203

Drug cost

$7,558

Median for Orthopedic Surgery: $1,433

Branded share of claims

17.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibuprofen Generic 220 $2,023
Diclofenac Sodium Generic 46 $1,428
Methylprednisolone Generic 146 $1,388
Celecoxib Generic 45 $1,020
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 78 $496
Tramadol Hcl Generic 117 $308
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 45 $303
Ondansetron Hcl Generic 26 $152
Gabapentin Generic 24 $138
Meloxicam Generic 53 $126

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 120 billing codes

Paid by Medicare

$117,583

Of which drugs: $19,938

Medicare patients

228

Average age 74

Services billed

6,407

150 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Ischemic heart disease 42%
Osteoporosis 42%
Diabetes 39%
Depression 36%
Chronic kidney disease 33%
Heart failure 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 19 1,184 $15,938
Injection, methylprednisolone acetate, 1 mg J1010 Office 43 3,440 $347
Injection, methylprednisolone acetate, 40 mg J1030 Office 20 32 $146
Injection, ketorolac tromethamine, per 15 mg J1885 Office 32 148 $79

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Tymlos
  • Radius Health, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record